Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade.

Lucy S WangRebecca A HubbardRonac Mamtani

Published in: Pharmacoepidemiology and drug safety (2024)

Our results provide reassurance that cisplatin-ineligible aUC patients receiving first-line immunotherapy in routine care experience similar benefits to those observed in trial patients.

Keyphrases

healthcare
end stage renal disease
palliative care
study protocol
clinical trial
chronic kidney disease
clinical practice
newly diagnosed
ejection fraction
quality improvement
pain management
prognostic factors
affordable care act
high grade
free survival
patient reported
urinary tract